# Landiolol for Rate Control in Decompensated Heart Failure Due to Atrial Fibrillation

> **NCT04694092** · NA · UNKNOWN · sponsor: **Institute for Clinical and Experimental Medicine** · enrollment: 40 (estimated)

## Conditions studied

- Atrial Fibrillation
- Atrial Fibrillation Rapid
- Acute Heart Failure
- Left Ventricular Dysfunction

## Interventions

- **DRUG:** Intensive heart rate control with landiolol
- **DRUG:** Standard approach to heart rate control

## Key facts

- **NCT ID:** NCT04694092
- **Lead sponsor:** Institute for Clinical and Experimental Medicine
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-05
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2021-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04694092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04694092, "Landiolol for Rate Control in Decompensated Heart Failure Due to Atrial Fibrillation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04694092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*